| Feature Type | Standardized | Nominal ANOVA | ||||
|---|---|---|---|---|---|---|
| mRNA | GDC-0879 | CTRPv2 | pan-cancer | AAC | 0.16 | 5e-05 |
| mRNA | GSK269962A | GDSC1000 | pan-cancer | AAC | -0.14 | 0.0001 |
| mRNA | PLX4720 | CTRPv2 | pan-cancer | AAC | 0.15 | 0.0002 |
| mRNA | lapatinib | CCLE | pan-cancer | AAC | 0.18 | 0.0003 |
| mRNA | XL-184 | GDSC1000 | pan-cancer | AAC | -0.14 | 0.0003 |
| mRNA | DMOG | GDSC1000 | pan-cancer | AAC | -0.13 | 0.0003 |
| mRNA | PLX4720 | CCLE | pan-cancer | AAC | 0.18 | 0.0004 |
| mRNA | erlotinib:PLX-4032 (2:1 mol/mol) | CTRPv2 | pan-cancer | AAC | 0.15 | 0.0005 |
| mRNA | foretinib | GDSC1000 | pan-cancer | AAC | -0.13 | 0.0005 |
| mRNA | AZD7762 | CTRPv2 | pan-cancer | AAC | -0.13 | 0.0006 |